News

STAT1y
FDA approves AstraZeneca, Ionis treatment for rare nerve disease
The drug is a monthly injection for a genetic disorder called ATTR-PN, which affects about 30,000 people around the world and can be fatal if left untreated.
MedPage Today1y
FDA Approves New Agent for Nerve Pain From Rare Inherited Disease
Eplontersen (Wainua) was approved by the FDA to treat polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (ATTR) in adults, Ionis Pharmaceuticals and AstraZeneca announced ...
Reuters1y
US FDA approves Ionis-AstraZeneca's nerve disease drug
The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease.
AOL1y
US FDA approves Ionis-AstraZeneca's nerve disease drug - AOL
The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease. The drug ...